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Fibronectin (FN) polymorphism is caused by alternative splicing patterns in at least three regions (ED-A, ED-B and IIICS) of the primary transcript 
of a single gene. Using monoclonal antibodies, we previously demonstrated that transforming growth factor-/l (TGF-B) preferentially increases 
the accumulation of the FN isoforms containing the ED-A sequence in cultured normal human fibroblasts [Balza et al., (1988) FEBS Lett. 228, 
42441. To determine the basis of this effect, we have examined through Sl nuclease analysis, the levels of ED-A- and ED-B-containing mRNAs 
in cultured normal human skin fibroblasts before and after TGF-j? treatment. These experiments have shown that TGF-#I increases the relative 
amount of m-RNA for ED-A- and ED-B-containing FN isoforms. These data demonstrate that a growth factor may regulate the splicing pattern 
of a pre-mRNA. 
Transforming growth factor-/I; Fibronectin isoform; Pre-mRNA splicing regulation 
1. INTRODUCTION 
Fibronectins (FNs) are high-molecular-mass adhesive 
glycoproteins present in soluble form in plasma and 
other body fluids and in insoluble form in the ex- 
tracellular matrices. FN molecules are involved in 
diverse biological phenomena, including the establish- 
ment and maintenance of normal cell morphology, cell 
migration, hemostatis and thrombosis, wound healing, 
and oncogenic transformation [l-4]. 
we have studied through Sl nuclease protection 
analysis, the levels of the ED-A and ED-B-containing 
FN mRNAs in three different lines of cultured human 
skin fibroblasts treated with TGF-,f3 and in untreated 
controls. The results demonstrate that the percentages 
of ED-A- and ED-B-containing FN mRNA increase 
from about 10 to 20 and from about 1 to 4.5, respective- 
ly, after TGF-fl treatment. 
2. MATERIALS AND METHODS 
FN polymorphism is caused by alternative splicing 
patterns in three regions of the primary transcript of a 
single gene which may generate 20 different FN subunit 
isoforms (fig.1) [5-73. The alternative splicing of FN 
pre-mRNA is regulated in a cell-, tissue- and develop- 
mentally specific manner [7-Ill. Furthermore, it has 
recently been demonstrated that the splicing pattern of 
FN pre-mRNA is deregulated in transformed cells and 
in malignancies [7,12]. In fact, IIICS, ED-A and ED-B 
sequences are expressed in a greater degree in 
transformed human cells as well as in tumor tissues with 
respect to their normal counterparts [7,13-161. 
Cultured normal fibroblasts from fetal (GM-5386) and non-fetal 
(GM-5659, GM3440) human skin were purchased from NIGMS (New 
Jersey, USA), and grown as in [18]. Cells were grown to confluence, 
then were treated for three days with a low concentration (0.3%) of 
fetal calf serum (FCS) medium. Subsequently, cells were treated for 
24 h with FCS-free medium containing 450 pM human platelet- 
derived TGF;Bi (R & D Systems, Minneapolis, MN) while the set of 
control cells was treated only with FCS-free medium. Cells were then 
washed and total RNA was extracted as in [19]. 
It has been shown that transforming growth factor-p 
(TGF-P) increases FN levels in both media and ex- 
tracellular matrix of a variety of cultured cells [17] and, 
using monoclonal antibodies, we have recently 
demonstrated that TGF-fi preferentially increases the 
accumulation of the ED-A-containing FN isoform [ 181. 
To investigate the molecular basis of this phenomenon, 
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The probe for the ED-A region was prepared as follows: a 752-base 
AccI-EcoRV fragment of the pFHll1 clone, kindly provided by Prof. 
F.E. Baralle (Istituto Sieroterapico Belfante, Milano, Italy) [8] was 
subcloned into AccI-SmaI sites of pGEM3Z (Progema, Madison, 
WI); the 613-base probe containing a FN sequence of 481 bases, in- 
cluding the complete ED-A sequence, plus 132 bases from the vector, 
was obtained by AvaII-PvuII digestion (figs.1 and 2A). The ED-B 
probe was prepared starting from the FN EcoRI insert of the clone A 
F2 [15] which contains the complete ED-B sequence plus 294 bases 
upstream and 252 bases downstream. This fragment was subcloned 
into the Ml3mpl9 vector. The 821-base double-stranded DNA probe, 
containing a FN sequence of 784 bases and 37 bases of the vector, was 
obtained by AccI digestion (figs. 1 and 3A). RNA Sl nuclease protec- 
tion analysis was carried out as in [20] using the ED-A probe, labelled 
with 32P at the 3 ’ end by end-filling as in [21] and ED-B probe 5 ’ end- 
labeled with “P using T4 polynucleatide kinase as in [22]. The 
nuclease-resistant fragments were analyzed on a 6% polyacrilamide 
gel containing 8 M urea, followed by autoradiography and double- 
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Fig. 1. Model of the domain structure of a human FN subunit. Arrows indicate the regions of variability due to alternative splicing of the FN mRNA 
precursors. The figure also indicates the internal homologies, macromolecules interacting with the various FN domains, the possible isoforms 
generated by alternative splicing of the pre-mRNA and the FN sequences covered by the probe used to study, by Sl nuclease analysis, the splicing 
patterns of the ED-A and ED-B exons. 
dimension analysis of the resulting film by an LKB Ultroscan XL laser 
densitometer. 
3. RESULTS 
Fig. 1 shows a schematic representation of the domain 
structure of the human FN, the possible isoforms 
generated by alternative splicing of the primary 
transcript and the sequences covered by the two probes 
used to study, by Sl nuclease analysis, the splicing pat- 
terns of the ED-A and ED-B exons. 
Fig.2A shows an autoradiogram of the Sl nuclease- 
resistant fragments of the cDNA probe, used to study 
the expression of the ED-A exon, protected by the 
hybridization with RNAs from a TGF-P-treated normal 
human skin fibroblast cell line (GM-5386) and from un- 
treated control cells. The results of similar studies using 
three different normal human fibroblast cell lines, show 
(fig.2B) that there is nearly a 2.0-2.5fold increase in 
the relative amount of the ED-A-containing FN mRNA 
molecules with respect o the controls, depending on the 
cell line. 
Fig.3A shows an autoradiogram of the Sl nuclease- 
resistant fragments of the cDNA probe, used to study 
the expression of the ED-B exon, protected by the 
hybridization with RNAs from a TGF-fl treated normal 
human skin fibroblast cell line (GM-5386) and from un- 
treated control cells. The results, obtained with similar 
experiments on RNAs from three different normal 
human skin fibroblast cell lines are shown in Fig.3B. 
The amount of FN mRNA molecules containing the 
ED-B sequence in TGF-P-treated cells increases 4-5 
176 
times with respect o the controls, depending on the cell 
line. 
4. DISCUSSION 
Alternative RNA splicing is an important flexible 
mechanism able to generate diversity in a reversible 
fashion in response to developmental and environmen- 
tal cues without requiring the expression of new genes 
[24-251. Nothing is known, however, about the ex- 
tracellular microenvironmental factors responsible for 
the modulation of splicing patterns of primary 
transcripts. 
It has been demonstrated that TGF-,&, released by 
platelet lysis, is sufficent to initiate the cascade of events 
resulting in the formation, of granulation tissue in 
wound healing and that the secretion of TGF-fi by 
tumor cells may have a similar effect on stromal 
elements ([26] and references therein), thus, suggesting 
that TGF-fl may be partially responsible for the higher 
expression of ED-A- and ED-B-containing FN isoforms 
observed in wound healing and tumor stroma compared 
to normal tissues [7,12-16,231. In our previous studies, 
addressed to verify this hypothesis, we have demon- 
strated, using monoclonal antibodies, that in cultured 
human fibroblasts, the relative amount of ED-A- 
containing FN increases about 2-3 times after TGF-P 
treatment [18]. Here we have now demonstrated that 
TGF-/3 also increases, in cultured human fibroblasts, 
the levels of ED-A- and ED-B-containing FN mRNA. 
On the contrary, dexamethasone, which also increases 
the total level of FN [27], does not change either the 
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Fig.2. Effect of TGF-b on the expression of the ED-A exon in normal 
human skin fibroblasts. (A) On the left we have depicted a schematic 
representation of the probe (see section 2) used to study, by Sl 
nuclease analysis, the splicing patterns of the ED-A exon. The se- 
quence deriving from the cloning vector at the 5 ’ end is indicated by 
a wavy line. The asterisk marks the 3’ ‘*P-labelled end. The probe 
fragments protected by the FN mRNA species containing (ED-A + ) 
or not containing (ED-A - ) the ED-A sequences are also shown. The 
autoradiogram shows an Sl nuclease analysis of mRNA from TGF- 
D-treated (lane 3) and untreated (lane 2) GM-5386 normal human 
fibroblasts. Lane 1: undigested probe. The numbers on the right of 
the autoradiogram indicate the size (in nucleotides) of the molecular 
weight markers. (B) The relative abundance of ED-A-containing FN 
mRNA in three different cell lines of normal human skin fibroblasts 
treated (dashed areas) and untreated (white areas) with TGF-,0. These 
results, obtained by laser densitometric scanning of autoradiograms 
deriving from experiments imilar to those shown in A, represent he 
average of three independent experiments in which the values differed 
by no more than 10%. 
relative amount of ED-A-containing FN [ 181 or the 
relative amount of ED-A-containing FN mRNA (data 
not shown). 
The data reported here suggest hat TGF-fl may con- 
trol the formation of stroma in granulation and tumor 
tissues, not only by increasing the accumulation of FN 
and other extracellular matrix proteins [26], but also by 
modifying the relative amount of the different FN 
isoforms. This is achieved through the modulation of 
the splicing of FN pre-mRNA, and possibly pre-mRNA 
of other extracellular matrix proteins as well, with a 
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Fig.3. Effect of TGF;O on the expression of the ED-B exon in normal 
human skin fibroblasts. (A) On the left there is a schematic represen- 
tation of the probe (see section 2) used to study, by Sl nuclease 
analysis, the splicing pattern of the ED-B exon. The sequence derived 
from the cloning vector, at the 3 ’ end, is indicated by a wavy line. The 
asterisk marks the 5’4abelled end. The probe fragments protected by 
FN mRNA species containing (ED-B+), and not containing (ED- 
B -) the ED-B sequence are also shown. The autoradiogram shows an 
Sl nuclease analysis of RNA from TGF-@treated (lane 3) and un- 
treated (lane 2) GM-5386 normal human fibroblasts. Lane 1: un- 
digested probe. The numbers on the right of the autoradiogram in- 
dicate the size (in nucleotides) of the molecular weight markers. (B) 
The relative abundance of ED-B-containing FN mRNA in three dif- 
ferent cell lines of normal human skin fibroblasts, treated (dashed 
areas) and untreated’(white areas) with TGF-b. These results, obtain- 
ed by laser densitometric scanning of autoradiograms deriving from 
experiments imilar to those shown in A, represent he average of 
three independent experiments in which the values differed by no 
more than 20%. 
consequent heightened expression of isoforms contain- 
ing extra sequences which may have specific biological 
functions. 
Furthermore, these data demonstrate for the first 
time, to our knowledge, that a growth factor may 
modulate the splicing pattern of a primary transcript. 
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